*.- Tienen 147 centros de donación en Estados Unidos, donde sí es legal su venta .
*.- Opina que en España las donaciones son gratuitas por un motivo 'romántico' .
*.- En una conferencia en la escuela de negocios Esade, el directivo de esta multinacional ha afirmado que si se permitiera el pago de donaciones, Grifols podría pagar "60 o 70 euros por semana" a un posible donante, que, "sumado al paro, es una forma de vivir", ha añadido.
...
A Comprehensive Safety Analysis Confirms Rhabdomyolysis as an Uncommon Adverse Reaction in Patients Treated with Trabectedin.
Grosso F, D'Incalci M, Cartoafa M, Nieto A, Fernández-Teruel C, Alfaro V, Lardelli P, Roy E, Gómez J, Kahatt C, Soto-Matos A, Judson I .
*.- PURPOSE: This analysis determined the incidence of serious rhabdomyolysis events reported during trabectedin treatment since the first phase I clinical trial in April 1996 up to September 2010.
*.- METHODS: Search was done in the Yondelis(®) Pharmacovigilance and Clinical Trials databases using a list of terms according to the Medical Dictionary for Regulatory Activities (MedDRA, v. 13.1), followed by a medical review of all cases retrieved. Total estimated sample was 10,841 patients: 2,789 from clinical trials; 3,926 from compassionate use programs; and 4,126 treated in the marketplace. Two groups were identified: (1) rhabdomyolysis and (2) clinically relevant creatine phosphokinase (CPK) increases without acute renal failure (ARF). Descriptive analysis included demographic, clinical/laboratory data, and contributing/confounding factors. Potential predictive factors were evaluated by multivariate stepwise logistic regression analysis. Possible changes of pharmacokinetics (PK) in patients with rhabdomyolysis were explored using a population PK model.
*.- RESULTS: The global incidence of rhabdomyolysis was 0.7 %, and most cases occurred in Cycle 2 of treatment. The incidence of fatal cases was 0.3 %. None of the variables evaluated to detect potential risk factors of rhabdomyolysis were predictive. Additionally, CPK increases (without ARF) were detected in 0.4 % of patients as an incidental finding with good prognosis.
*.- CONCLUSIONS: Rhabdomyolysis is an uncommon event during trabectedin treatment. Multivariate analyses did not show any potential factor that could be predictive or represent a significantly higher risk of developing rhabdomyolysis. Nevertheless, close patient monitoring and adherence to drug administration guidelines may help to limit the incidence of this event .